Last edition
News about "Major depressive disorder (MDD)"
Suven Life Sciences reported positive phase 2b results for Ropanicant in Major Depressive Disorder (MDD), achieving significant improvements in depression symptoms versus placebo. The treatment showed favorable safety and tolerability, with no withdrawal symptoms or dissociation, supporting advancement into a global phase 3 study.
Major Depressive Disorder (MDD) | 17/06/2026 | By News Bureau | 261
Zydus Lifesciences Receives USFDA Tentative Nod for Generic Multiple Sclerosis Drug
Zydus Lifesciences has received tentative approval from the United States Food and Drug Administration (USFDA) for Diroximel Fumarate delayed-release capsules, 231 mg, a generic version of Vumerity delayed-release capsules of the same strength.
Major Depressive Disorder (MDD) | 13/11/2025 | By Dineshwori | 423
Alembic Wins USFDA Clearance for Paroxetine ER Tablets for Depression and Anxiety Disorders
Alembic Pharmaceuticals has received final approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Paroxetine Extended-Release Tablets USP, 25 mg and 37.5 mg.
Major Depressive Disorder (MDD) | 25/09/2025 | By Dineshwori | 182
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy